Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
作者信息
Besson Guillaume J, McMahon Deborah, Maldarelli Frank, Mellors John W
出版信息
Clin Infect Dis. 2012 Feb 1;54(3):451-3. doi: 10.1093/cid/cir721. Epub 2011 Oct 19.
Abstract
摘要
相似文献
1
Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy.
Clin Infect Dis. 2012 Feb 1;54(3):451-3. doi: 10.1093/cid/cir721. Epub 2011 Oct 19.
2
Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.
J Theor Biol. 2014 Mar 21;345:61-9. doi: 10.1016/j.jtbi.2013.12.020. Epub 2013 Dec 28.
3
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.
J Infect Dis. 2013 Nov 1;208(9):1436-42. doi: 10.1093/infdis/jit453. Epub 2013 Aug 23.
4
No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy.
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.
5
Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
J Antimicrob Chemother. 2010 Mar;65(3):434-7. doi: 10.1093/jac/dkp473. Epub 2010 Jan 5.
6
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.
7
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
AIDS. 2010 Sep 24;24(15):2391-5. doi: 10.1097/QAD.0b013e32833d214c.
8
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
Antivir Ther. 2012;17(2):355-64. doi: 10.3851/IMP1917. Epub 2011 Sep 28.
9
Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
AIDS. 2012 Jan 14;26(2):167-74. doi: 10.1097/QAD.0b013e32834e8955.
10
Viral persistence in HIV infection: much known, much to learn.
J Infect Dis. 2013 Nov 1;208(9):1356-8. doi: 10.1093/infdis/jit455. Epub 2013 Aug 23.
引用本文的文献
1
Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
Viruses. 2020 Apr 27;12(5):489. doi: 10.3390/v12050489.
2
Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.
Clin Drug Investig. 2019 Dec;39(12):1239-1249. doi: 10.1007/s40261-019-00840-2.
3
Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV.
J Clin Invest. 2019 Jul 22;129(8):3361-3373. doi: 10.1172/JCI120633.
4
Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane.
Proc Natl Acad Sci U S A. 2018 Mar 13;115(11):E2575-E2584. doi: 10.1073/pnas.1720665115. Epub 2018 Feb 26.
5
Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence.
Retrovirology. 2018 Jan 30;15(1):15. doi: 10.1186/s12977-018-0398-1.
6
Prolonged persistence of a novel replication-defective HIV-1 variant in plasma of a patient on suppressive therapy.
Virol J. 2016 Sep 21;13(1):157. doi: 10.1186/s12985-016-0617-0.
7
How to Define the Latent Reservoir: Tools of the Trade.
Curr HIV/AIDS Rep. 2016 Apr;13(2):77-84. doi: 10.1007/s11904-016-0304-1.
8
A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.
Biores Open Access. 2016 Jan 1;5(1):15-21. doi: 10.1089/biores.2015.0038. eCollection 2016.
9
Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.
Lancet HIV. 2015 Mar;2(3):e82-91. doi: 10.1016/S2352-3018(15)00026-0. Epub 2015 Feb 17.
10
The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
mBio. 2015 Jul 7;6(4):e00465. doi: 10.1128/mBio.00465-15.
本文引用的文献
1
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.
J Infect Dis. 2011 Apr 1;203(7):960-8. doi: 10.1093/infdis/jiq138.
2
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.
3
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
PLoS Med. 2010 Aug 10;7(8):e1000321. doi: 10.1371/journal.pmed.1000321.
4
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
Nat Med. 2010 Apr;16(4):460-5. doi: 10.1038/nm.2111. Epub 2010 Mar 14.
5
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749.
6
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.
Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8. doi: 10.1073/pnas.0903107106. Epub 2009 May 22.
7
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
PLoS Pathog. 2007 Apr;3(4):e46. doi: 10.1371/journal.ppat.0030046.
Zotero 插件